Abstract: A medical information processing apparatus according to an embodiment includes a processing circuitry. The processing circuitry is configured: to distribute, to an information processing apparatus provided at each of a plurality of medical institutions, a program for causing a machine learning process to be executed by using medical data held at the medical institution having the information processing apparatus; to receive, from each of the information processing apparatuses, a change amount in a parameter related to the machine learning process, regarding a change caused in conjunction with the execution of the machine learning process; to adjust a value of the parameter on the basis of the received change amount; and to transmit the adjusted parameter to each of the information processing apparatuses to cause the machine learning process to be executed on the basis of the parameter.

Abstract: A medical information processing apparatus according to an embodiment includes a processing circuitry. The processing circuitry is configured: to evaluate each of a plurality of machine learning models on a basis of an output result from each of the machine learning models obtained by inputting mutually the same medical data to the machine learning models and success/failure judgment results on the output results, the plurality of machine learning models being created from a plurality of pieces of medical data and either created from at least partially mutually-different medical data or created under mutually-different parameter conditions; and to cause results of the evaluation on the machine learning models to be displayed in such a manner that comparison is possible.

Abstract: A medical image diagnosis apparatus for use in a therapeutic procedure to a subject includes processing circuitry. The processing circuitry is configured to determine a status of a current therapeutic procedure; determine at least one proposed preset of settings of the medical image diagnosis apparatus according to the status of the current therapeutic procedure; and perform a control in accordance with the at least one proposed preset.

Abstract: Provide a safer cutting machine. A front portion detection means that is spaced downward from the lower end of the clamp gauge by a first predetermined distance and is positioned near the front edge of the clamp gauge in die front-rear direction of the clamp gauge, and a first predetermined distance from the lower end of the clamp gauge. The rear portion detection means and the clamp gauge which arc spaced apart from each other by a second predetermined distance different from the above distance and which are arranged at the rear portion of the front portion detection means in the front-rear direction of the clamp gauge move in the vertical direction.

Abstract: A medical information processing apparatus according to an embodiment includes a processing circuitry. The processing circuitry is configured: to distribute, to an information processing apparatus provided at each of a plurality of medical institutions, a program for causing a machine learning process to be executed by using medical data held at the medical institution having the information processing apparatus; to receive, from each of the information processing apparatuses, a change amount in a parameter related to the machine learning process, regarding a change caused in conjunction with the execution of the machine learning process; to adjust a value of the parameter on the basis of the received change amount; and to transmit the adjusted parameter to each of the information processing apparatuses to cause the machine learning process to be executed on the basis of the parameter.

Abstract: A medical information processing apparatus according to an embodiment includes a processing circuitry. The processing circuitry is configured: to evaluate each of a plurality of machine learning models on a basis of an output result from each of the machine learning models obtained by inputting mutually the same medical data to the machine learning models and success/failure judgment results on the output results, the plurality of machine learning models being created from a plurality of pieces of medical data and either created from at least partially mutually-different medical data or created under mutually-different parameter conditions; and to cause results of the evaluation on the machine learning models to be displayed in such a manner that comparison is possible.

Abstract: Provided is a compound which is useful as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. The present inventors have investigated compounds having a 5-HT2C receptor agonist activity and have found that the benzazepine compounds of the present invention have an excellent 5-HT2C receptor agonist activity, thereby completing the present invention. That is, the benzazepine compounds of the present invention have a 5-HT2C receptor agonist activity and can be used as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.

Abstract: Provided is a compound which is useful as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. The present inventors have investigated compounds having a 5-HT2C receptor agonist activity and have found that the benzazepine compounds of the present invention have an excellent 5-HT2C receptor agonist activity, thereby completing the present invention. That is, the benzazepine compounds of the present invention have a 5-HT2C receptor agonist activity and can be used as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.

Abstract: Provided is a compound which is useful as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. The present inventors have investigated compounds having a 5-HT2C receptor agonist activity and have found that the benzazepine compounds of the present invention have an excellent 5-HT2C receptor agonist activity, thereby completing the present invention. That is, the benzazepine compounds of the present invention have a 5-HT2C receptor agonist activity and can be used as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.

Abstract: Provided is a compound which is useful as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. The present inventors have investigated compounds having a 5-HT2C receptor agonist activity and have found that the benzazepine compounds of the present invention have an excellent 5-HT2C receptor agonist activity, thereby completing the present invention. That is, the benzazepine compounds of the present invention have a 5-HT2C receptor agonist activity and can be used as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.

Abstract: Provided is a compound which is useful as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. The present inventors have investigated compounds having a 5-HT2C receptor agonist activity and have found that the benzazepine compounds of the present invention have an excellent 5-HT2C receptor agonist activity, thereby completing the present invention. That is, the benzazepine compounds of the present invention have a 5-HT2C receptor agonist activity and can be used as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.

Abstract: [Problem] Provided is a compound which is useful as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. [Means for Solution] The present inventors have investigated compounds having a 5-HT2C receptor agonist activity, which is promising as an active ingredient of a pharmaceutical composition for treating or preventing incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like, and have found that the benzazepine compounds of the present invention have an excellent 5-HT2C receptor agonist activity, thereby completing the present invention.